The FDA granted approval to pexidartinib (Turalio, Daiichi Sankyo) capsules for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery.
A rare tumor, TGCT affects the synovium and tendon sheaths. The tumor is rarely malignant but causes the synovium and tendon sheaths to thicken and overgrow, damaging the surrounding tissue.